Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 73

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 73
---
,520,735          Operating loss  (10,817,147)  (10,520,735)         Other (expenses) income        Other income  108,484   460,485 Warrant expense  (7,323,685)    Changes in fair value of warrant liability  3,447,737     Gain on settlement of warrant exercise  3,076,664     Total other expenses  (690,800)  460,485          Loss from operations before income taxes  (11,507,947)  (10,060,250)         Provision for income taxes  -   -          Net Loss $(11,507,947) $(10,060,250)         Net loss per share – basic and diluted $(56.94) $(2,766.85)         Weighted average common shares – basic and diluted  202,106   3,636 

The accompanying notes are an integral part of these consolidated financial statements.

 F-3 

ENDRA Life Sciences Inc.

Consolidated Statements of Stockholders’ Equity

Year Ended December 31, 2023  Series A Convertible  Series B Convertible             Total    Preferred Stock  Preferred Stock  Common stock  Additional    Accumulated  Stockholders’   Shares   Amount  Shares   Amount  Shares   Amount  Paid in Capital  Stock Payable  Deficit  Equity Balance as of December 31, 2022   141.397  $1   -  $-   1,811  $-  $89,068,332  $6,073  $(81,869,902) $7,204,504 Common stock issued for cash, net of funding costs  -   -   -   -   3,221   1   6,483,392   -   -   6,483,393 Common stock issued for warrant exercise  -   -   -   -   905   -   1,014,859   -   -   1,014,859 Warrants issued for cash, net of funding